| pubmed-article:16855074 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16855074 | lifeskim:mentions | umls-concept:C1708335 | lld:lifeskim |
| pubmed-article:16855074 | lifeskim:mentions | umls-concept:C0018810 | lld:lifeskim |
| pubmed-article:16855074 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:16855074 | lifeskim:mentions | umls-concept:C0871269 | lld:lifeskim |
| pubmed-article:16855074 | lifeskim:mentions | umls-concept:C0599724 | lld:lifeskim |
| pubmed-article:16855074 | lifeskim:mentions | umls-concept:C0388088 | lld:lifeskim |
| pubmed-article:16855074 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:16855074 | pubmed:dateCreated | 2006-7-20 | lld:pubmed |
| pubmed-article:16855074 | pubmed:abstractText | The purpose of this double-blind, placebo-controlled study was to measure the effects of FTY720, a novel immunomodulator, on heart rate and rhythm in healthy volunteers. Subjects (n = 66) were randomized to FTY720 1.25 mg or 5 mg or placebo administered once daily for 7 days. Continuous telemetry revealed an acute, dose-dependent decrease in mean heart rate (10-bpm decrease vs placebo) following the first dose of FTY720, with a nadir generally 4 hours postdose. Although a persistent FTY720-related decrease in heart rate was measured from day 2 to day 7, additional doses of FTY720 after day 2 resulted in no further incremental decreases. Mean PR interval increased by approximately 8 to 10 msec in FTY720-treated subjects on day 1. FTY720 did not increase the QRS or QT interval. These results confirm that the first dose of FTY720 has a mild to moderate negative chronotropic effect. | lld:pubmed |
| pubmed-article:16855074 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16855074 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16855074 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16855074 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16855074 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16855074 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16855074 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16855074 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16855074 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:16855074 | pubmed:issn | 0091-2700 | lld:pubmed |
| pubmed-article:16855074 | pubmed:author | pubmed-author:KovarikJohn... | lld:pubmed |
| pubmed-article:16855074 | pubmed:author | pubmed-author:WangYibinY | lld:pubmed |
| pubmed-article:16855074 | pubmed:author | pubmed-author:HuntThomas... | lld:pubmed |
| pubmed-article:16855074 | pubmed:author | pubmed-author:DiMarcoJohnJ | lld:pubmed |
| pubmed-article:16855074 | pubmed:author | pubmed-author:SchmouderRobe... | lld:pubmed |
| pubmed-article:16855074 | pubmed:author | pubmed-author:BastienMarie-... | lld:pubmed |
| pubmed-article:16855074 | pubmed:author | pubmed-author:SerraDeniseD | lld:pubmed |
| pubmed-article:16855074 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16855074 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:16855074 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16855074 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16855074 | pubmed:pagination | 895-904 | lld:pubmed |
| pubmed-article:16855074 | pubmed:dateRevised | 2008-6-5 | lld:pubmed |
| pubmed-article:16855074 | pubmed:meshHeading | pubmed-meshheading:16855074... | lld:pubmed |
| pubmed-article:16855074 | pubmed:meshHeading | pubmed-meshheading:16855074... | lld:pubmed |
| pubmed-article:16855074 | pubmed:meshHeading | pubmed-meshheading:16855074... | lld:pubmed |
| pubmed-article:16855074 | pubmed:meshHeading | pubmed-meshheading:16855074... | lld:pubmed |
| pubmed-article:16855074 | pubmed:meshHeading | pubmed-meshheading:16855074... | lld:pubmed |
| pubmed-article:16855074 | pubmed:meshHeading | pubmed-meshheading:16855074... | lld:pubmed |
| pubmed-article:16855074 | pubmed:meshHeading | pubmed-meshheading:16855074... | lld:pubmed |
| pubmed-article:16855074 | pubmed:meshHeading | pubmed-meshheading:16855074... | lld:pubmed |
| pubmed-article:16855074 | pubmed:meshHeading | pubmed-meshheading:16855074... | lld:pubmed |
| pubmed-article:16855074 | pubmed:meshHeading | pubmed-meshheading:16855074... | lld:pubmed |
| pubmed-article:16855074 | pubmed:meshHeading | pubmed-meshheading:16855074... | lld:pubmed |
| pubmed-article:16855074 | pubmed:meshHeading | pubmed-meshheading:16855074... | lld:pubmed |
| pubmed-article:16855074 | pubmed:meshHeading | pubmed-meshheading:16855074... | lld:pubmed |
| pubmed-article:16855074 | pubmed:meshHeading | pubmed-meshheading:16855074... | lld:pubmed |
| pubmed-article:16855074 | pubmed:meshHeading | pubmed-meshheading:16855074... | lld:pubmed |
| pubmed-article:16855074 | pubmed:meshHeading | pubmed-meshheading:16855074... | lld:pubmed |
| pubmed-article:16855074 | pubmed:meshHeading | pubmed-meshheading:16855074... | lld:pubmed |
| pubmed-article:16855074 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16855074 | pubmed:articleTitle | FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. | lld:pubmed |
| pubmed-article:16855074 | pubmed:affiliation | Exploratory Development, Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA. | lld:pubmed |
| pubmed-article:16855074 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16855074 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:16855074 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16855074 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16855074 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16855074 | lld:pubmed |
